Trastuzumab has been shown to be useful in a wide range of circumstances, including recurrent cases and pre- and postoperative adjuvant chemotherapy for HER2-positive breast cancer, making it an indispensable drug in clinical practice [3]. The gene discussed is ERBB2; the disease is breast carcinoma.